MedTrace Logo

Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency

NCT00498628 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2019-03-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether quetiapine fumarate extended release is effective in the treatment of alcohol dependence in very heavy drinkers.

Conditions

  • Alcoholism
  • Alcohol Abuse

Interventions

DRUG

Quetiapine fumarate

Quetiapine fumarate- taken daily, for 12 weeks

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Raye Z. Litten, PhD · National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  • Margaret E. Mattson, PhD · National Institute on Alcohol Abuse and Alcoholism (NIAAA)

  • Joanne Fertig, PhD · National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-08-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498628 on ClinicalTrials.gov